
MAL2 Rabbit pAb

Catalog Number: bs-7175R

Target Protein: MAL2

Concentration: 1mg/ml

Form: Liquid

Host: Rabbit

Clonality: Polyclonal

Isotype: IgG

Applications: IHC-P (1:100-500), IHC-F (1:100-500), IF (1:100-500)

Reactivity: Human (predicted:Mouse, Rat, Pig, Cow)

Predicted MW: 19 kDa

Entrez Gene: 114569

Swiss Prot: Q969L2

Source: KLH conjugated synthetic peptide derived from human MAL2: 21-120/176.


Purification: affinity purified by Protein A

Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background: The MARVEL domain is a 130 amino acid motif that contains four transmembrane helices, both of which have cytoplasmic N- and C-terminal regions. MARVEL domain-containing proteins are thought to participate in tight junction regulation, the biogenesis of vesicular transport carriers and in cholesterol-rich membrane apposition events. MAL2 (mal, T-cell differentiation protein 2) is a 176 amino acid multi-pass membrane protein that is associated with lipid rafts and contains one MARVEL domain. Expressed predominately in liver, kidney and lung, MAL2 functions as a member of the polarized machinery transport system and is required for transcytosis, a transporter pathway used to deliver membrane-bound cargo from perinuclear endosomes to the apical surface in a raft-dependent manner. Differential expression of MAL2 is associated with several cancers, including renal cell carcinoma and childhood leukemia, suggesting a role for MAL2 in tumorigenesis.

VALIDATION IMAGES



Paraformaldehyde-fixed, paraffin embedded (human liver carcinoma); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (MAL2) Polyclonal Antibody, Unconjugated (bs-7175R) at 1:400 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructions and DAB staining.

PRODUCT SPECIFIC PUBLICATIONS

[IF=9.423] Jaekwang Jeong. et al. MAL2 mediates the formation of stable HER2 signaling complexes within lipid raft-rich membrane protrusions in breast cancer cells. Cell Rep. 2021 Dec;37:110160 IF ; Human . 34965434

[IF=7.919] Le Tao. et al. FTO modifies the m6A level of MALAT and promotes bladder cancer progression. Clin Transl Med. 2021 Feb;11(2):e310 IHC ; Human . 33634966

[IF=5.875] Feiyang Deng. et al. Lipid raft-mediated and upregulated coordination pathways assist transport of glycocholic acid-modified nanoparticle in a human breast cancer cell line of SK-BR-3. Int J Pharmaceut. 2022 Apr;617:121589 IF ; Human . 10.1016/j.ijpharm.2022.121589

[IF=5.8] An Lijun. et al. Downregulation of MAL2 inhibits breast cancer progression through regulating β -catenin/c-Myc axis. CANCER CELL INT. 2023 Dec;23(1):1-10 WB,IHC ; Human . 37480012

[IF=2.9] Dong Zhou. et al. Integrated whole-exome and bulk transcriptome sequencing delineates the dynamic evolution from preneoplasia to invasive lung adenocarcinoma featured with ground-glass nodules. CANCER MED-US. 2024 Jun;13(11):e7383 WB ; Human . 10.1002/cam4.7383